AI assistant
Syncona Limited — Director's Dealing 2019
Jul 18, 2019
6283_rns_2019-07-18_c941a500-8e81-482a-bb06-334b19de52e3.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 0316G
Syncona Limited
18 July 2019
Syncona Limited
Issue of shares pursuant to the 2019 dividend and PDMR dealings
18 July 2019
Syncona Limited (the "Company") today announces that a total of 860,090 new ordinary shares will be issued in satisfaction of the payment of the Company's 2019 dividend to those qualifying shareholders who did not elect to receive the dividend in cash. The new ordinary shares, when issued, will rank pari passu with the existing issued ordinary shares of the Company.
Application has been made to the Financial Conduct Authority for the shares to be admitted to the Official List, and to the London Stock Exchange for the shares to be admitted to trading and it is expected that dealings will commence in the new ordinary shares on 29 July 2019.
Notification of transactions by Persons Discharging Managerial Responsibilities ("PDMRs") are set out below.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver / Annabel Clay
Tel: +44 (0) 20 3981 7940
FTI Consulting
Brett Pollard / Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000
Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.
We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of genetic medicine, particularly gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.
1.
Details of PDMR / person closely associated with them ("PCA")
a)
Name
Martin Murphy
b)
Position / status
Chief Executive Officer, SIML
c)
Initial notification / amendment
Initial Notification
2.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Ordinary shares
GG00B8P59C08
b)
Nature of the transaction
Acquisition of shares under the 2019 Dividend
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| 2.281 | 3,094 |
d)
Aggregated information
Aggregated volume
Price
N/A
e)
Date of the transaction
18 July 2019
f)
Place of the transaction
Outside a trading venue
g)
Currency
GBP - British Pound
1.
Details of PDMR / person closely associated with them ("PCA")
a)
Name
Jeremy Tigue
b)
Position / status
Chairman
c)
Initial notification / amendment
Initial Notification
2.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Ordinary shares
GG00B8P59C08
b)
Nature of the transaction
Acquisition of shares under the 2019 Dividend
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| 2.281 | 4,820 |
d)
Aggregated information
Aggregated volume
Price
N/A
e)
Date of the transaction
18 July 2019
f)
Place of the transaction
Outside a trading venue
g)
Currency
GBP - British Pound
1.
Details of PDMR / person closely associated with them ("PCA")
a)
Name
Ellen Strahlman
b)
Position / status
Non-Executive Director
c)
Initial notification / amendment
Initial Notification
2.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Ordinary shares
GG00B8P59C08
b)
Nature of the transaction
Acquisition of shares under the 2019 Dividend
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| 2.281 | 1,584 |
d)
Aggregated information
Aggregated volume
Price
N/A
e)
Date of the transaction
18 July 2019
f)
Place of the transaction
Outside a trading venue
g)
Currency
GBP - British Pound
1.
Details of PDMR / person closely associated with them ("PCA")
a)
Name
Robert Hutchinson
b)
Position / status
Non-Executive Director
c)
Initial notification / amendment
Initial Notification
2.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Ordinary shares
GG00B8P59C08
b)
Nature of the transaction
Acquisition of shares under the 2019 Dividend
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| 2.281 | 432 |
d)
Aggregated information
Aggregated volume
Price
N/A
e)
Date of the transaction
18 July 2019
f)
Place of the transaction
Outside a trading venue
g)
Currency
GBP - British Pound
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
IOELLFSSDAITLIA